PMID- 32627959
OWN - NLM
STAT- MEDLINE
DCOM- 20210604
LR  - 20210604
IS  - 2045-7634 (Electronic)
IS  - 2045-7634 (Linking)
VI  - 9
IP  - 16
DP  - 2020 Aug
TI  - Efficacy and safety of low-dose apatinib in ovarian cancer patients with 
      platinum-resistance or platinum-refractoriness: A single-center retrospective 
      study.
PG  - 5899-5907
LID - 10.1002/cam4.3282 [doi]
AB  - BACKGROUND: This study aimed to evaluate the efficacy and safety of apatinib with 
      a low dose of 250 mg/d in the treatment of platinum-resistant or 
      platinum-refractory ovarian cancer patients. METHODS: Patients with 
      platinum-resistant or platinum-refractory ovarian carcinoma treated with 250 mg/d 
      apatinib in our institution from November 2016 to December 2017 were 
      retrospectively reviewed. The tumor response and progression were evaluated 
      according to the standard by incorporating the levels of CA125 and Response 
      Evaluation Criteria in Solid Tumors 1.1. CTCAE 4.03 was used to evaluate adverse 
      events (AEs). RESULTS: Fifty-two eligible patients were enrolled in per-protocol 
      (PP) analysis and 65 patients (including 13 lost to follow-up) were included in 
      the intention-to-treat (ITT) analysis. In PP analysis, 18 patients (34.6%) had 
      partial response (PR), 22 patients (42.3%) had stable disease (SD), and the 
      disease control rate (DCR) was 61.5%. Median progression-free survival (PFS) was 
      4.0 months (95% CI, 2.83-5.17 m), and median overall survival (OS) was 
      25.33 months (95% CI, 17.74-32.92 m). The objective response rate and DCR for 
      patients in ITT analysis were 27.7% and 49.2%, respectively. The top three 
      treatment-related AEs were hypertension, hand-foot syndrome, and leukopenia. 
      Eight patients (15.4%) in PP population had grade 3 treatment-related AEs. 
      Previous chemotherapy lines, number of recurrences, and AEs did not affect the 
      efficacy of apatinib. Age older than 60 was associated with higher rates of 
      disease control and prolonged PFS (P < .05). CONCLUSION: Apatinib 250 mg/d is a 
      feasible treatment in platinum-resistant or platinum-refractory epithelial 
      ovarian cancer (EOC) patients.
CI  - (c) 2020 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
FAU - Chen, Wei
AU  - Chen W
AUID- ORCID: 0000-0002-8159-5514
AD  - Department of Gynecologic Oncology, Department of Oncology, Fudan University 
      Shanghai Cancer Center, Shanghai Medical College, Fudan University, Shanghai, 
      China.
AD  - Department of Obstetrics and Gynecology, Minhang Hospital Fudan University, The 
      Central Hospital of Minhang District, Shanghai, China.
FAU - Li, Ziting
AU  - Li Z
AD  - Department of Gynecologic Oncology, Department of Oncology, Fudan University 
      Shanghai Cancer Center, Shanghai Medical College, Fudan University, Shanghai, 
      China.
FAU - Zheng, Zhong
AU  - Zheng Z
AUID- ORCID: 0000-0002-8175-698X
AD  - Department of Gynecologic Oncology, Department of Oncology, Fudan University 
      Shanghai Cancer Center, Shanghai Medical College, Fudan University, Shanghai, 
      China.
FAU - Wu, Xiaohua
AU  - Wu X
AUID- ORCID: 0000-0002-6889-3541
AD  - Department of Gynecologic Oncology, Department of Oncology, Fudan University 
      Shanghai Cancer Center, Shanghai Medical College, Fudan University, Shanghai, 
      China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200706
PL  - United States
TA  - Cancer Med
JT  - Cancer medicine
JID - 101595310
RN  - 0 (Antineoplastic Agents)
RN  - 0 (CA-125 Antigen)
RN  - 0 (MUC16 protein, human)
RN  - 0 (Membrane Proteins)
RN  - 0 (Platinum Compounds)
RN  - 0 (Pyridines)
RN  - 5S371K6132 (apatinib)
SB  - IM
MH  - Adult
MH  - Age Factors
MH  - Aged
MH  - Antineoplastic Agents/*administration & dosage/adverse effects
MH  - CA-125 Antigen/blood
MH  - Disease Progression
MH  - Drug Resistance, Neoplasm
MH  - Feasibility Studies
MH  - Female
MH  - Hand-Foot Syndrome/etiology
MH  - Humans
MH  - Hypertension/chemically induced
MH  - Intention to Treat Analysis
MH  - Leukopenia/chemically induced
MH  - Membrane Proteins/blood
MH  - Middle Aged
MH  - Ovarian Neoplasms/blood/*drug therapy/mortality
MH  - Platinum Compounds/therapeutic use
MH  - Progression-Free Survival
MH  - Pyridines/*administration & dosage/adverse effects
MH  - Response Evaluation Criteria in Solid Tumors
MH  - Retrospective Studies
PMC - PMC7433830
OTO - NOTNLM
OT  - angiogenesis inhibitor
OT  - apatinib
OT  - epithelial ovarian cancer
OT  - low dose
OT  - platinum-resistant
EDAT- 2020/07/07 06:00
MHDA- 2021/06/05 06:00
PMCR- 2020/07/06
CRDT- 2020/07/07 06:00
PHST- 2020/03/15 00:00 [received]
PHST- 2020/05/27 00:00 [revised]
PHST- 2020/06/11 00:00 [accepted]
PHST- 2020/07/07 06:00 [pubmed]
PHST- 2021/06/05 06:00 [medline]
PHST- 2020/07/07 06:00 [entrez]
PHST- 2020/07/06 00:00 [pmc-release]
AID - CAM43282 [pii]
AID - 10.1002/cam4.3282 [doi]
PST - ppublish
SO  - Cancer Med. 2020 Aug;9(16):5899-5907. doi: 10.1002/cam4.3282. Epub 2020 Jul 6.